Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 Ml3SSpVv[3Srb36gRZN{[Xl? M1ny[|AvP87:TR?= NEDpcGszPGh? NHj2XFlmfGijbn;s NXqwRZN[\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= Ml7RNlU4QDdyN{m=
TE13 M1fJTWZ2dmO2aX;uJGF{e2G7 NUjsU5g6OC5|zszN NYfJWo9tOjSq NVzMSlUyfXBvcnXneYxifGW|IGLBV3NHPUFibHX2[Yw> NIewbZkzPTV5OU[2OS=>
TE13 M3WxdGFxd3C2b4Ppd{BCe3OjeR?= MlTmNE4{|ryP MUWyOIg> MWXpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v MWSyOVU4QTZ4NR?=
MEFs M{XEZWZ2dmO2aX;uJGF{e2G7 MojoOe69VQ>? M{P1b|E3cA>? MXnpcoNz\WG|ZYOgeIhmKEWSRVOgZZR1[WOqbXXueEwhXGm{IHTlcIl3\XK7IHHu[EB1cGViZX\mbYNq\W6leTDv[kBx\WSnc4ThcEBnd3KvYYTpc44> M3LCbFI2PDh{NkO0
SW480  NGHZZZRHfW6ldHnvckBCe3OjeR?= MWCwMlHPxE1? MV[0PIg> NYXNOVVtTE2VTx?= MmLXdoV3\XK|ZYOgSW1V NVHofXNGOjV2M{S5PVc>
PC3  NF7QbY5HfW6ldHnvckBCe3OjeR?= NX7McI41OC5zzszN M{C3N|Q5cA>? NXHqSHZSTE2VTx?= NED0cFJz\X[ncoPld{BGVVR? NUXFXZNtOjV2M{S5PVc>
SW480  NFy5UmFHfW6ldHnvckBCe3OjeR?= M1nmPFAvOc7:TR?= NUHHRoRYPDiq M{LYZWROW09? MWPheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? MofyNlU1OzR7OUe=
PC3  MojFSpVv[3Srb36gRZN{[Xl? NFWwOZIxNjIQvF2= MnzPOFhp MkHzSG1UVw>? NIDJb4xifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MWmyOVQ{PDl7Nx?=
SW480  MXfGeY5kfGmxbjDBd5NigQ>? MVSwMlHPxE1? M2\6OVQ5cA>? MVHEUXNQ MlvObY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NITqSZAzPTR|NEm5Oy=>
PC3  NG\FV|BHfW6ldHnvckBCe3OjeR?= MWGwMlHPxE1? MX20PIg> Moi3SG1UVw>? NHXyXXpqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ MkC0NlU1OzR7OUe=
A431 NFW1ZXNCeG:ydH;zbZMhSXO|YYm= NUKw[mVzOi9zMD:1NE8yODCwTR?= MV[0PIg> MUjEUXNQ M2XCbYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?= M1rGTlI2OzdzME[5
A431 NGnwcm5HfW6ldHnvckBCe3OjeR?= Ml7SOVBvVQ>? NWS4PW9POi94L{GyM|I1cA>? MV;EUXNQ Ml32ZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w MYqyOVM4OTB4OR?=
MDA-MB-231 M2P0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMVYxOG6P NIPjNJEzPGh? NF:4cW9FVVOR MlL6TWM2OCCxZjCxNFBvVQ>? MWOyOVE6Ojd{MR?=
MCF7 NHrxWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLhWZYxNTZyMH7N NFTUVW8zPGh? M1[yOmROW09? NVuzWoU1UUN3MDDv[kA4PW6P NFi0T2kzPTF7MkeyNS=>
SKOV-3 M1LjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLKNU0yOM7:TR?= MoHTNlRp MVLEUXNQ NVXYPY95UUN3MDDv[kA2NjcQvF2= NYTIT446OjVzNkm0PVE>
A549 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDGNU0yOM7:TR?= MlHPNlRp NV3qO2d[TE2VTx?= NHSwVoJKSzVyIH;mJFMvOs7:TR?= NF2zeZIzPTF4OUS5NS=>
SKOV-3 M{PMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMlEuOc7:TR?= MlK2OFhp M3TibWROW09? NU[ycIxIUUN3MDDv[kAxNjgQvF2= M4fFflI2OTZ7NEmx
A549 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGwMlEuOc7:TR?= NIPpUoI1QGh? M1HoUWROW09? M1jFTmlEPTBib3[gNE4zQM7:TR?= NYnmPXM{OjVzNkm0PVE>
SKOV-3 NWPnSmRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rHOlAvODFvMD65{txO NELwN3E4Omh? NXm1[pBXTE2VTx?= MWTJR|UxKG:oIECuN|LPxE1? NGm1ZZozPTF4OUS5NS=>
A549 M1vRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fSW|AvODFvMD65{txO NFzke5M4Omh? M4LlW2ROW09? MWXJR|UxKG:oIECuNFbPxE1? MnnVNlUyPjl2OUG=
HeLa MVPGeY5kfGmxbjDBd5NigQ>? NG\uUHozPTCwTR?= MnWwNVZp NVToPIhbTE2VTx?= MWnpcoNz\WG|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi M1LrXFI2OTF4Nki4
CNE2 NILBe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWzUI0yODBvNkCwcm0> NHy2RWwzPC92OD:3Nog> NX;VZYh7cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz M2r5XVI1QTZ7OUCx
PC3 NVnzXWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNFAuOTByMH7N MXmyOIg> NW\wWIZYUUN3MDDv[kA{ODCwTR?= MmiyNlQ5PTR4NUi=
LNCaP NH\4b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rHdFExOC1zMECwcm0> NInGZnkzPGh? MX;JR|UxKG:oIEOwNI5O NES3WoQzPDh3NE[1PC=>
HeLa  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPKPWEz|ryP NXz2cJR4PDiq Ml7H[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= NH7w[4QzPDh2NkGzOS=>
HMEC-1  M1TYemZ2dmO2aX;uJGF{e2G7 M1;odFMxOG6P NXjiSZZjOjSq MknEbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> MkXWNlQ4OTB4M{G=
HeLa MnXlSpVv[3Srb36gRZN{[Xl? M37aZlFuVQ>? Ml31NE42cA>? NIPD[Y9i[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= Ml21NlQ4ODd2N{S=
ACP02 NFP2[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX1S4ozPTBxM{WwM|UxOG6P NUXkNZpCOjSq MkTl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NXvGZ4U2OjR4Nki1OFc>
ACP03 MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW2cllpOjVyL{O1NE82ODCwTR?= M2D5d|I1cA>? NW\FdYlX\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MnrpNlQ3Pjh3NEe=
U87 GBM MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXWNVAxNzNyMD:1NFAhdk1? NWm3PI9DPzJiaB?= Ml7qNVAxLSCndHjhco9t M4f6UJJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> MVyyOFQ3PDh2MR?=
U87 GBM MojhSpVv[3Srb36gRZN{[Xl? MWOxNFAwPTByIF7t NX3Pd5hZPDhiaB?= NXrPT4RqOTByJTDleIhidm:u M1PYbGlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? MmPENlQ1PjR6NEG=
RPE MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7qWFlIOC5{L{CuOE8xNjhxMTFOwG0> M3jncFI1NzR6L{eyJIg> MUPEUXNQ Ml\qbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> NHm0UJkzPDR3Nk[wNi=>
HT29  MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH1O2NROThyIH7N NUPFe5NtPzJiaB?= M37vRWlEPTBib3[gNVgxKG6P NVPhWVYxOjR|NkiyOlU>
hMSCs NVvIWIR{TnWwY4Tpc44hSXO|YYm= M4XrUVYvOjVibl2= MmLONlQhcA>? MnnMSG1UVw>? M33sXpN1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= M3ziWVI1OzF{M{W2
Huh7  MVXGeY5kfGmxbjDBd5NigQ>? MVSwMlEwOC53L{GuNEDPxE1? MljtNlRp NWLTc4pFe3WycILld5NmeyC\VFjER|Ih\2WwZTDlfJBz\XO|aX;u NInUN3kzPDJ4OU[3Ni=>
SKOV3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknQNE4xPS1{IN88US=> M3vUNFExNzJ2L{S4JIg> NH;obWdFVVOR NHfadoFu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MYqyOFIzOzhyMR?=
A2780 NUjGWI5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmwPVFmOC5yNT2yJO69VQ>? NUXZNVg{OTBxMkSvOFghcA>? M1LF[mROW09? NHO1[JBu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M1fZSFI1OjJ|OECx
SRA01/04  NHHTUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH0PFkxNjJizszN NYnQUYlUPDhiaB?= NYG3eXF7TE2VTx?= MYTzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> M{HMS|I1OTV5OEe4
HLEB3 NIXERWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInmVWQxNjJizszN M2Czb|Q5KGh? MVHEUXNQ MmP2d5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> NXy3TFZNOjRzNUe4O|g>
SRA01/04  MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ewTFAvPC9yLkig{txO NWnobmpUPDhiaB?= M2TTUWROW09? NVrTUFVmcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MnnhNlQyPTd6N{i=
HLEB3 NGjBR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX1VoF{OC52L{CuPEDPxE1? NYO5cWF3PDhiaB?= MXrEUXNQ MnvObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NIfifpEzPDF3N{i3PC=>
HCT116 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqUlAvOiEQvF2= MYOxNkBp NHrQcZhmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JJJi\GmjdHnvci=> MontNlQyOjJ{M{G=
CA46 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW2XlU{NzZxMUKvNlQwPDhibl2= MoK1OFghcA>? M4i0XIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? MUSyOFA3PDl3MR?=
PMNs M3z3U2Z2dmO2aX;uJGF{e2G7 NXzQW4VqOzBibl2= NHrz[WI1QCCq MonhbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 MlXENlM6QDh4MUe=
H1299 M4nZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxxsDPxE4EoB?= NHfnUY8zPC92OD:3NkBp NVfubpVU\XSqYX7vcC=> NGjBW2tqdmO{ZXHz[ZMh[2WubDDk[YF1cCCjZoTldkAzPGh? NEWxdVUzOzlzNk[wPS=>
A549 M3XsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPPNE4zPS9yLkWvNUDPxE1? MWiyOE81QC95MjDo MkDL[ZRp[W6xbB?= NH3YW2hqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M4fNbVI{QDZ5OUmx
H1299 NES5e|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjKNW8xNjJ3L{CuOU8yKM7:TR?= NEPiZlAzPC92OD:3NkBp MkHq[ZRp[W6xbB?= NGnqXYxqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NUTQO5NYOjN6Nke5PVE>
A549 MonRRZBweHSxc3nzJGF{e2G7 NX\JSmJHOC53L{Gg{txO Mne0OFghcA>? NH7r[HhmfGijbn;s MknabY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVzXfWlbOjN6Nke5PVE>
H1299 MX;BdI9xfG:|aYOgRZN{[Xl? NImwZmwxNjVxMTFOwG0> MnjEOFghcA>? NVe1bVZr\XSqYX7vcC=> NFHxbW9qdmS3Y3XzJINmdGxiYYDvdJRwe2m| NF;yWGIzOzh4N{m5NS=>
SUM149PT M3TycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS5Nk84NjVxMUCg{txO NInKXm81QCCq NHvDbWlFVVOR MYLpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? M3P1eFI{Pzl{NkO4
SUM190PT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy1NE8yODBxMkWwJI5O M2i0c|Q5KGh? Mn;mSG1UVw>? MWHpcoR2[2W|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk> NYPwRXZ4OjN5OUK2N|g>
HCT1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KzOlAvOi9zLkCvOU4xKM7:TR?= NYfqeHB1OTJxMkSvN|YwPDhiaB?= MmPDbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NYHCbpB{OjN5N{CwNFA>
Lovo M33wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGyWmh[OC5{L{GuNE82NjBizszN MYGxNk8zPC9|Nj:0PEBp NHvZ[I1qdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MkjTNlM4PzByMEC=
AGS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;YTWcxNjBzNT2xJO69VQ>? MYG3NkBp MVnpcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= M16xUFI{PzR3MEK0
Huh7 NHzDd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPobnMyKM7:TR?= MYOyOEBp MVrEUXNQ MWDy[YR2[2W|IHHic5V1KDJyJTD2bYFjcWyrdIpCpC=> M1G4c|I{PjR|OUOz
ECC1 NVXadYVkTnWwY4Tpc44hSXO|YYm= NFe1cYs2ODBibl2= MVK1JIQ> M3TXNmROW09? MWLpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? M37MclI{PTNyN{[5
HEC1A MUDGeY5kfGmxbjDBd5NigQ>? NUi0OpVnPTByIH7N NGTMOYY2KGR? NX;jb4NnTE2VTx?= M2XxOIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MlO4NlM2OzB5Nkm=
EN1 NITDOWFHfW6ldHnvckBCe3OjeR?= MlS5OVAxKG6P NVryXZBNPSCm NILTVotFVVOR MUDpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? M1nZfFI{PTNyN{[5
MFE296 M1fXdmZ2dmO2aX;uJGF{e2G7 NIWwZVc2ODBibl2= MlnpOUBl NWe2XJpITE2VTx?= NUfZcnN6cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= MWiyN|U{ODd4OR?=
HASMCs MV\GeY5kfGmxbjDBd5NigQ>? NY\HO4FCOC13MECgcm0> NIPkSmc3KGR? MVPkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> MYGyN|UyQDR4Nx?=
U373 NILOT|NHfW6ldHnvckBCe3OjeR?= NWfIWY5FOC5{NT:wMlUwOSEQvF2= NVrLblFyOjRiaB?= MXrpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? NGTrVlczOzR5NEG3NS=>
ARN8  M1rVTWZ2dmO2aX;uJGF{e2G7 M2jIcFAvODVvMjFOwG0> M2S5b|I1KGh? NYfjc20{emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NFuzV4szOzR5MEW0NC=>
MCF7 NH3le5hHfW6ldHnvckBCe3OjeR?= M2XpbVAvODVvMjFOwG0> MkDSNlQhcA>? MWjy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> MojVNlM1PzB3NEC=
H1299  M3;3V2Z2dmO2aX;uJGF{e2G7 NYXDdndXOC5|M,MAl|HDqML3TR?= MYeyOE81QCCq NFriZpdFVVOR NEH4VYNqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 M3m3TFI{PDZzOUe1
H1299 NHvJSG1HfW6ldHnvckBCe3OjeR?= NX7Nc|RQOC53IN88US=> Mo\zOFghcA>? NV\yXpRRTE2VTx?= NXrGOXU5cW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MYKyN|Q3OTl5NR?=
H1299 NXXPPWF2TnWwY4Tpc44hSXO|YYm= MnjqNE42KM7:TR?= MkXyOFghcA>? NF3KZndFVVOR MXfpcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? NWPvN4NzOjN2NkG5O|U>
MG-63  NYnwTIVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSwMlMh|ryP MXSxNk06PiCq Mm\jSG1UVw>? MW\pcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw NIrhRVYzOzR3MUixOy=>
LM8 NWT3fo9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX0THgxNjNizszN M{[zVVEzNTl4IHi= MnrISG1UVw>? MnzDbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MmjzNlM1PTF6MUe=
K562 M163RWZ2dmO2aX;uJGF{e2G7 NGnP[5oxNjVizszN MlLVNlQhcA>? MnLU[ZRp[W6xbB?= NGLxPVRl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NF3Fd5czOzR|MEm1Oy=>
HEL NUXuVJplTnWwY4Tpc44hSXO|YYm= MX[wMlUh|ryP M1T6T|I1KGh? M2X5WIV1cGGwb3y= M3\YNYRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv MXSyN|Q{ODl3Nx?=
HL60 NFvqdoVCeG:ydH;zbZMhSXO|YYm= MmHBNUDPxE1? MXeyOEBp NHfMN2pqdmS3Y3XzxsBk\WyuIHTlZZRp M4nJXlI{PDByNUG5
KG1 NGS4PJRCeG:ydH;zbZMhSXO|YYm= MVexJO69VQ>? M{jQfVI1KGh? MkDWbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MXOyN|QxODVzOR?=
Kazumi MVjBdI9xfG:|aYOgRZN{[Xl? Ml3QNUDPxE1? NV74VnRJOjRiaB?= MXnpcoR2[2W|wrDj[YxtKGSnYYTo NWPHXmFCOjN2MEC1NVk>
K562 NELJZZNCeG:ydH;zbZMhSXO|YYm= M2DuUlEh|ryP NUfwTFFUOjRiaB?= MkfabY5lfWOnc9MgZ4VtdCCmZXH0bC=> MU[yN|QxODVzOR?=
THP1 MkfHRZBweHSxc3nzJGF{e2G7 Mk\ONUDPxE1? NEntbXQzPCCq NHvTXY5qdmS3Y3XzxsBk\WyuIHTlZZRp MmTLNlM1ODB3MUm=
SH-SY5Y M4G3[GZ2dmO2aX;uJGF{e2G7 MnLsNlUxKG6P M{[zVlE3KGh? M4TWcINp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= NGq3R5czOzN{NkSyNi=>
HEK293 M1PmS2Z2dmO2aX;uJGF{e2G7 M17wW|EhyrWPwrC= NE[2TI4yQCCqwrC= M1KzO4lvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? MnrYNlMzQDR6NEi=
HTK NYXGSHFbTnWwY4Tpc44hSXO|YYm= NVXN[3BlPDByIH7N MWW3NkBp MUXpcohq[mm2czDUS2Yu|rMkgKPJcoR2[2WmIF35c4Zq[nKxYnzhd5QhTGmoZnXy[Y51cWG2aX;u NWHpVGw3OjN{OESwNFI>
HTK M3;LPGZ2dmO2aX;uJGF{e2G7 MYCxNFAuQDBybl2= NHGxV5U4OiCq M{\6foJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w MkXCNlMzQDRyMEK=
Caco-2  M1TlVWZ2dmO2aX;uJGF{e2G7 M2nuUFEhyrWPwrC= M1izXFI1KGh? NFLreIJl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= MojJNlMyQTVyN{C=
HeLa MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNFAhdk1? MWeyOEBp NU\uOZdKTE2VTx?= MYfJR|UxKG:oIEGwNI5O NHXORYYzOzF4NUe0PC=>
HeLa MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjZXFh4PDBibl2= MlLmOFghcA>? MWrEUXNQ MWHJR|UxKG:oIESwcm0> NHO3SJgzOzF4NUe0PC=>
HeLa NXfQN|B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfWS3hNOjBibl2= NFS3bpc4OiCq NEPJN2hFVVOR NXHaWm9FUUN3MDDv[kAzOG6P MUSyN|E3PTd2OB?=
HeLa NVH1[Y5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf4VmQ3OTBxM{CvOVAhdk1? MmL2O|IhcA>? M2raSmROW09? M163Xolv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> NGDvXIIzOzF4NUe0PC=>
MDA-MB-231 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWeyOU01ODBibl2= Mne3OFghcA>? NHfnZ4ZKSzVyIH;mJFI3Oy5{bl5CpC=> M4O1e|I{ODV3MUm4
MCF-7  M1HGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHFRVMzPS12MECgcm0> NWW0O5RvPDhiaB?= MVXJR|UxKG:oIEKyNE41dk1? NX;rdHlTOjNyNUWxPVg>
ECC-1  MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO4NVAxKG6P M1;3bFI1KGh? M1v0WIV1cGGwb3y= MnzzbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn NXXjNINSOjNyMki4NFM>
HEC-1A NYflfFBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WyeVExOCCwTR?= NXLw[4ltOjRiaB?= MoPn[ZRp[W6xbB?= M3:2V4lv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= NH\DWJQzOzB{OEiwNy=>
NHAC-kn MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLPNVAwOTByL{WwNEBvVQ>? MXixNkBp MVvEUXNQ M2DmWmlEPTBib3[gOVAxdk1? M4faXlI{ODF5OEex
A549 M2DRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[yOVAhdk1? MnS1Ok04OiCq M{XuXGROW09? NWfDdmxO[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? NIXkVG0zOjl7NEe4NC=>
MG-63 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6yN|AxKG6P M{HOSlEzKGh? MlqxSG1UVw>? NWiyeJlrcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= MmrkNlI4QTl|M{i=
MG-63 NUH6Xm5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrnT3RIOzByIH7N NV;R[It3OjRiaB?= MYHEUXNQ NVW2ZppZcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= NGDRSpgzOjd7OUOzPC=>
MG-63 NUXmN3dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnkN|AxKG6P MYG0PEBp NFH3c4tFVVOR NHHkZWFqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn NWXSTJBpOjJ5OUmzN|g>
HL60  M4DvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnzWodKOTVyLUO1NEBvVQ>? M3W4TlI1KGh? NXnFVmZIcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NF[3S|MzOjd3M{ezPS=>
U937 NV7SdFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jHdlE2OC1|NUCgcm0> MlHxNlQhcA>? NFLQbZJqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O NWTDdXpVOjJ5NUO3N|k>
SCC-6 NGXNXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XONVIxOC1|MkCwJI5O M1vSOVEzNzJ2L{S4JIg> NIXoWZFFVVOR NIrNN3RqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MlvBNlI2PTJ|MkG=
U87  NFPkfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTzR4hbOTByLUOwNEBv\w>? MkPqNlQhcA>? NF:wVWpqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= NGDtZ5czOjJ5MEi0PS=>
K562 MX\GeY5kfGmxbjDBd5NigQ>? NFvh[o0yKM7:TR?= MVuxNkBp M2PxR2ROW09? NETqXllmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> M3LLVlIzOTd7MUm4
Reh NFrwWZNHfW6ldHnvckBCe3OjeR?= MU[wMlMwOSEQvF2= NH7KbZAyOiCq NWLCOllITE2VTx?= MXLlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= M3\5dlIzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03735173 Not yet recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT02959905 Unknown status Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT03133819 Enrolling by invitation Diabetes; Neuropathy Polyneuropathy (Manifestation) Chang Gung Memorial Hospital November 2016 Not Applicable
NCT02486965 Recruiting Fibromyalgia University Hospital Brest October 2015 Not Applicable
NCT01954433 Active not recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG) Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Completed Pain Massachusetts General Hospital June 2012 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID